I see general oncology patients and patients with rare liver cancer. My clinical focus is tied to my research in neuroblastoma.
Neuroblastoma is the pediatric cancer whose genetics we know most about. Many neuroblastoma patients do well, but others have a very aggressive form of the disease. But until now, the tools for determining who's at greatest risk of relapse haven't been precise. We need to find genetic markers that could help identify the patients who could potentially benefit from more intensive therapy. Finding the genes involved in aggressive neuroblastoma also will help us develop targeted therapeutic agents.
My colleagues and I are looking at the biology of the neuroblastoma cell – the critical cell pathways that will help us identify how to better treat the disease and prevent relapse. Our goal is to understand what can interrupt and treat the disease: what genes and changes in the neuroblastoma cell explain why they became a cancer.
The genetics of cancer has long been an interest of mine. As I progressed through my medical education, the concept of cancer being a disease of the genome (DNA) became more and more apparent to me. I realized there were genes that control how fast cells grow and when they stop growing. I saw how this connected with medicine -- and found I wanted to unite my clinical and scientific interests in the study of genomics.
Our clinical research at Children's Hospital focuses on critical changes in the genome and the specific chromosomes associated with the worst patient neuroblastoma outcomes. Using microarrays DNA technology, we are trying to understand how cells change. Next, we will be able to move beyond learning about a single gene to sequencing the entire genome.
Our goal is to identify certain cell subtypes within neuroblastoma. Every child's cancer is different, but understanding the subtypes means we can better target the individual cancer cell abnormality and tailor the therapy to each individual patient. More specifically, our genome work involves analysis of tissue samples from children with neuroblastoma to determine the relationship between disease progression and an abnormal deletion in the "q" arm of chromosome 11. We found that patients with chromosome 11q and chromosome 1p deletion are more likely to have aggressive neuroblastoma. Identifying these genetic markers is helping us better design therapies to potentially improve patient survival.
When it comes to caring for our patients with neuroblastoma and other pediatric cancers, my approach with patients and families has always been to make the child the focus of the care. I help the child communicate what he or she is experiencing. And since there is a lot of uncertainly revolving around cancer treatment, I try to anticipate what our patients and their families are thinking -- and let them know the possibilities and status of their situation.
One of the most attractive things about working in oncology at Children's Hospital, along with our top clinicians and researchers, is the broader staff involved. The nurses, social worker and psychologists are all specifically dedicated to work with our special cancer population.
- Education and Training
MD - Albert Einstein College of Medicine, New York, NY
Pediatrics - Yale-New Haven Children's Hospital, New Haven, CT
Pediatric Hematology/Oncology - Children's Hospital of Philadelphia, Philadelphia, PA
AB in Molecular Biology - Princeton University, Princeton, N.J.
- Titles and Academic Titles
Vice-Chair, CHOP Institutional Review Board
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
- Departments and Services
Attiyeh EF: Rhabdomyosarcoma. In: Schwartz MW, editor. The 5-minute pediatric consult. Philadelphia: Lippincott Williams & Wilkins; 2008.
Attiyeh EF: Neuroblastoma. In: Schwartz MW, editor. The 5-minute pediatric consult. Philadelphia: Lippincott Williams & Wilkins; 2008.
Attiyeh EF: Ewing Sarcoma. In: Schwartz MW, editor. The 5-minute Pediatric Consult. Philadelphia: Lippincott Williams & Wilkins; 2008.
Ranieri P, Trillo R, Landesman Y, Senapedis W, McCauley D, Shacham S, Kauffman M, Maris JM, and Attiyeh EF: Inhibition of exportin 1 (XPO1) by selinexor (KPT-330) synergistically suppresses growth of neuroblastoma in combination with doxorubicin or bromodomain inhibition. Proceedings of the American Association for Cancer Research Annual Meeting Apr 2015.
Attiyeh EF, Ranieri P, Trillo R, Landesman Y, Senapedis W, McCauley D, Kashyap T, Shacham S, Kauffman M, Maris JM: Inhibition of Exportin 1 (XPO1) potently suppresses growth of human neuroblastoma cell lines. Proceedings of the Advances in Neuroblastoma Research Bi-Annual Meeting May 2014.
Attiyeh EF, McKeon-Fish A, Landesman Y, Senapedis W, McCauley D, Kashyap T, Shacham S, Kauffman M, Maris JM: Targeted inhibition of Chromosomal Maintenance Region Protein (CRM1) potently suppresses growth of human neuroblastoma cell line models. Proceedings of the American Association for Cancer Research Annual Meeting Apr 2013.
Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ. A LIN28B-RAN-AURKA signaling network promotes neuroblastoma tumorigenesis. Cancer Cell. 2015 Nov 9;28(5):599-609.
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015 Aug;47(8):864-71.
Rader Julieann, Russell Mike R, Hart Lori S, Nakazawa Michael S, Belcastro Lili T, Martinez Daniel, Li Yimei, Carpenter Erica L, Attiyeh Edward F, Diskin Sharon J, Kim Sunkyu, Parasuraman Sudha, Caponigro Giordano, Schnepp Robert W, Wood Andrew C, Pawel Bruce, Cole Kristina A, Maris John M: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 19(22): 6173-82, Nov 2013.
Pugh Trevor J, Morozova Olena, Attiyeh Edward F, Asgharzadeh Shahab, Wei Jun S, Auclair Daniel, Carter Scott L, Cibulskis Kristian, Hanna Megan, Kiezun Adam, Kim Jaegil, Lawrence Michael S, Lichenstein Lee, McKenna Aaron, Pedamallu Chandra Sekhar, Ramos Alex H, Shefler Erica, Sivachenko Andrey, Sougnez Carrie, Stewart Chip, Ally Adrian, Birol Inanc, Chiu Readman, Corbett Richard D, Hirst Martin, Jackman Shaun D, Kamoh Baljit, Khodabakshi Alireza Hadj, Krzywinski Martin, Lo Allan, Moore Richard A, Mungall Karen L, Qian Jenny, Tam Angela, Thiessen Nina, Zhao Yongjun, Cole Kristina A, Diamond Maura, Diskin Sharon J, Mosse Yael P, Wood Andrew C, Ji Lingyun, Sposto Richard, Badgett Thomas, London Wendy B, Moyer Yvonne, Gastier-Foster Julie M, Smith Malcolm A, Auvil Jaime M Guidry, Gerhard Daniela S, Hogarty Michael D, Jones Steven J M, Lander Eric S, Gabriel Stacey B, Getz Gad, Seeger Robert C, Khan Javed, Marra Marco A, Meyerson Matthew, Maris John M: The genetic landscape of high-risk neuroblastoma. Nature genetics 45(3): 279-84, Mar 2013.
Chand Damini, Yamazaki Yasuo, Ruuth Kristina, Schönherr Christina, Martinsson Tommy, Kogner Per, Attiyeh Edward F, Maris John, Morozova Olena, Marra Marco A, Ohira Miki, Nakagawara Akira, Sandström Per-Erik, Palmer Ruth H, Hallberg Bengt: Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Disease models & mechanisms 6(2): 373-82, Mar 2013.
Posters and Presentations
Goryeb Children's Hospital Grand Rounds: "Hereditary Cancer Predisposition in Children", February 2015.
Goryeb Children's Center Grand Rounds: "Hereditary Cancer Predisposition in Children", February 2015.
- Awards and Honors
2008, Advances in Neuroblastoma Research (ANR) Best Paper
2006-2009, ASCO Foundation Career Development Award
2005, ASCO Foundation Brigid Leventhal Merit Award
2005-2007, AACR-Pennsylvania Department of Health Fellowship in Basic Cancer Research
2005-2006, ASCO Foundation Young Investigator Award
2005, ASCO Foundation Fellowship Merit Award
2005-2007, Children's Neuroblastoma Cancer Foundation Award
2004-2008, William Guy Forbeck Research Foundation Scholar
- Editorial and Academic Positions
2014-present, British Journal of Cancer
2013-present, European Journal of Medical Genetics
2012-present, Cancer Genetics
2012-present, Cancer Research
2012-present, Clinical Cancer Research
2011-present, New England Journal of Medicine
2011-present, American Journal of Pathology
2010-present, Journal of Molecular Diagnostics
2010-present, Briefings in Bioinformatics
2010-present, Nucleic Acids Research
2009-present, BMC Cancer
2008-present, Journal of Pediatric Hematology/Oncology
2006-present, Pediatric Blood and Cancer
Academic and Institutional Committees
2014-present, Vice-chair, Institutional Review Board (IRB)
2010-present, Co-chair, Children's Oncology Group Non-High-Risk Neuroblastoma Task Force
2008-present, Member, Oncology Pediatric Protocol Review Committee
2008-present, Member, Institutional Review Board (IRB)
2006-present, Children's Oncology Group Neuroblastoma Biology Committee
2006-present, Children's Oncology Group ANBL0531 Study Committee
Memberships in Professional Organizations
2006-present, Children's Oncology Group (COG)
2003-present, American Society of Clinical Oncology (ASCO)
2003-present, American Association for Cancer Research (AACR)
2002-present, American Society of Pediatric Hematology/Oncology (ASPHO)
- Awards and Honors